Mitsubishi UFJ Asset Management
ALXN

Mitsubishi UFJ Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84,504
Closed -$15.5M – 1137
2021
Q2 		$15.5M Buy
84,504
+11,328
+15% +$1.94M 0.08% 261
2021
Q1 		$11.2M Buy
73,176
+10,105
+16% +$1.56M 0.07% 302
2020
Q4 		$9.85M Buy
63,071
+2,950
+5% +$379K 0.08% 283
2020
Q3 		$6.88M Buy
60,121
+9,375
+18% +$1.01M 0.06% 313
2020
Q2 		$5.7M Buy
50,746
+6,757
+15% +$717K 0.07% 302
2020
Q1 		$3.95M Sell
43,989
-614
-1% -$60.3K 0.06% 304
2019
Q4 		$4.75M Buy
44,603
+5,496
+14% +$588K 0.06% 314
2019
Q3 		$3.83M Buy
39,107
+1,712
+5% +$193K 0.06% 306
2019
Q2 		$4.9M Buy
37,395
+7,410
+25% +$955K 0.08% 243
2019
Q1 		$4.05M Buy
29,985
+1,651
+6% +$205K 0.08% 236
2018
Q4 		$2.84M Sell
28,334
-1,574
-5% -$186K 0.07% 265
2018
Q3 		$4.16M Sell
29,908
-325
-1% -$40.8K 0.09% 225
2018
Q2 		$3.75M Sell
30,233
-273
-0.9% -$31.9K 0.08% 237
2018
Q1 		$3.4M Sell
30,506
-4,088
-12% -$489K 0.08% 255
2017
Q4 		$4.32M Buy
34,594
+1,293
+4% +$157K 0.09% 224
2017
Q3 		$4.67M Buy
33,301
+995
+3% +$135K 0.11% 197
2017
Q2 		$3.93M Sell
32,306
-3,731
-10% -$434K 0.1% 219
2017
Q1 		$4.37M Buy
36,037
+1,323
+4% +$171K 0.1% 214
2016
Q4 		$4.26M Buy
34,714
+171
+0.5% +$20.9K 0.1% 208
2016
Q3 		$4.23M Buy
34,543
+879
+3% +$113K 0.11% 201
2016
Q2 		$3.93M Buy
33,664
+908
+3% +$129K 0.1% 203
2016
Q1 		$4.56M Buy
32,756
+2,736
+9% +$402K 0.12% 169
2015
Q4 		$5.73M Buy
30,020
+1,933
+7% +$338K 0.17% 124
2015
Q3 		$4.39M Sell
28,087
-81
-0.3% -$14.8K 0.14% 142
2015
Q2 		$5.09M Buy
28,168
+1,505
+6% +$260K 0.16% 127
2015
Q1 		$4.62M Sell
26,663
-1,426
-5% -$258K 0.14% 157
2014
Q4 		$5.24M Sell
28,089
-3,890
-12% -$721K 0.16% 137
2014
Q3 		$5.3M Sell
31,979
-6,503
-17% -$1.07M 0.16% 141
2014
Q2 		$6.01M Buy
38,482
+51
+0.1% +$8.05K 0.15% 153
2014
Q1 		$5.85M Buy
38,431
+2,403
+7% +$382K 0.16% 153
2013
Q4 		$4.75M Sell
36,028
-9,056
-20% -$1.09M 0.14% 169
2013
Q3 		$5.24M Buy
45,084
+2,384
+6% +$262K 0.14% 169
2013
Q2 		$3.94M Buy
+42,700
New +$4.11M 0.11% 214

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Mitsubishi UFJ Asset Management's ALXN Position: Q3 2021 in Review

Mitsubishi UFJ Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 84,504 shares — an estimated $15.5M sold.

Mitsubishi UFJ Asset Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $15.5M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mitsubishi UFJ Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 84,504 Alexion Pharmaceuticals shares in Q3 2021, an estimated $15.5M.
  • Mitsubishi UFJ Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Mitsubishi UFJ Asset Management's Alexion Pharmaceuticals position peaked at $15.5M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.